Industry Calls For Reform of England’s Unused Innovative Medicines Fund
Executive Summary
The pharmaceutical industry says financial uncertainties are a key reason why the English Innovative Medicines Fund (IMF) – offering the potential for time-limited funding for promising non-cancer treatments where benefits are uncertain at launch - has still not been used a year after it was put in place. Industry wants the National Health Service to share the financial risk of taking part in the fund.
You may also be interested in...
England’s Unused Innovative Medicines Fund Under Fire Again
A group of UK academics have broadly welcomed the fund that will pay for innovative non-cancer drugs, but have expressed concern over issues such as the entry criteria and the definition of “high unmet need.” They also say safeguards are needed against possible financial loss to the National Health Service.
Ipsen Accuses Government Of Backward Step With Proposed Changes to Statutory Pricing Scheme
Ipsen and other experts have criticized proposals from the UK government on changes to the statutory scheme for the pricing of branded medicines. Plans for differential rebates are seen as too complex, meaning their impact is difficult to predict and they could end up costing the government more.
UK Government And Industry Still Far Apart In Talks on New Pricing Scheme
The UK pharmaceutical industry association, the ABPI, says it and the government are still far from reaching a deal on a new voluntary pricing agreement and has suggested that a transition to the statutory scheme could be on the cards if an acceptable deal cannot be secured.